Molecular hydrogen improves type 2 diabetes through inhibiting oxidative stress.
Ming Y, Ma QH, Han XL, Li HY · Experimental and therapeutic medicine · 2020
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
The publication “Molecular hydrogen improves type 2 diabetes through inhibiting oxidative stress.” is organized in H2HUBB under the research focus injected hydrogen diabetes metabolic study 2020. The publication is cited as Ming Y, Ma QH, Han XL, Li HY, Experimental and therapeutic medicine, 2020. This animal study examined Molecular hydrogen improves type 2 diabetes through inhibiting oxidative stress. The abstract describes Rat model; hydrogen delivered as injected or infused hydrogen; reported duration 4 weeks. The abstract reports: The results showed that in rats with T2DM, molecular hydrogen treatment decreased fasting blood glucose levels, increased hepatic glycogen synthesis and improved insulin sensitivity. This is an automated editorial draft based on the abstract and requires source review before publication.
Injected hydrogen diabetes metabolic study 2020 overview
The aim of the present study was to investigate the potential therapeutic effects of molecular hydrogen on type 2 diabetes mellitus (T2DM) in rats. Animal research can identify biological effects and support future investigation, but it cannot by itself establish safety or effectiveness in humans.
Study design and hydrogen intervention
Publication type: Animal study. Evidence type: Preclinical animal evidence. Research model or population: Rat model. Blinding: Unknown. Control status: Unknown.
Delivery method: Injected or infused hydrogen. Treatment duration: 4 weeks.
Reported findings and scientific interpretation
For this injected hydrogen diabetes metabolic study 2020, the study record reports the following: The abstract reports: The results showed that in rats with T2DM, molecular hydrogen treatment decreased fasting blood glucose levels, increased hepatic glycogen synthesis and improved insulin sensitivity.
These findings should be interpreted as one piece of evidence rather than as a stand-alone medical conclusion. Results can be influenced by the research model, study design, treatment protocol, sample size, outcome selection, statistical methods, and whether the findings have been independently reproduced.
How this research record was prepared
H2HUBB organizes bibliographic details, study design information, intervention data, outcomes, limitations, and safety notes from the available scientific source. Automated classification supports database organization, but it does not replace critical reading of the complete paper. Source identifiers, evidence labels, and delivery-method fields are retained so readers can verify the record and compare it with related publications. A missing field means the information was unavailable or not reported in the structured source; it should not be treated as a negative finding.
Limitations, safety, and original source
Limitations: Preclinical animal findings may not translate directly to human outcomes.
Safety: The abstract did not provide detailed safety or adverse-event information.
This H2HUBB page is an educational research record, not medical advice. Review the original scientific source for the complete methods and results. Continue exploring the H2HUBB Molecular Hydrogen Research Library to compare evidence types, delivery methods, and related topics.